Nuvectis Pharma, Inc. (NASDAQ: NVCT) has priced its previously announced underwritten public offering of 5 million shares of common stock at $20.00 per share, expected to generate gross proceeds of approximately $100 million. The offering, which includes a 30-day option for underwriters to purchase up to an additional 750,000 shares at the same price, is slated to close on or about July 1, 2026, subject to customary closing conditions.
The company intends to use the net proceeds to advance development of its lead programs: NXP100, NXP200, and NXP900. NXP100 is a late-stage Factor B inhibitor with best-in-class potential for complement-mediated diseases, offering a once-daily oral treatment option. NXP900 is an oral small molecule inhibitor targeting the SRC Family of Kinases, while NXP200 is a brain-penetrant, paradox-breaker BRAF inhibitor for various solid tumor malignancies. Additionally, funds will support future product candidates, hiring, capital expenditures, and general corporate purposes.
The offering is led by Cantor as sole book-running manager, with co-managers including H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners. This financing underscores investor confidence in Nuvectis' pipeline and its potential to address significant unmet medical needs.
Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on innovative therapies for immune complement-related conditions and oncology. The company's pipeline also includes NXP100, a complement Factor B inhibitor, and oncology candidates NXP900 and NXP200. For more information, visit Nuvectis Pharma.
This announcement is important as it provides Nuvectis with substantial capital to advance multiple promising drug candidates through clinical development, potentially bringing new treatment options to patients with complement-mediated diseases and various cancers. The dosing of the offering at $20 per share reflects strong market support for the company's strategy and pipeline.
